Sovran Advisors LLC Buys Shares of 5,020 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Sovran Advisors LLC purchased 5,020 shares of Regeneron Pharmaceuticals, valued at approximately $2.75 million, during the second quarter.
• Several analysts have issued buy ratings for Regeneron Pharmaceuticals, with price targets ranging from $650 to $850, reflecting a consensus rating of "Moderate Buy".
• The company reported $12.89 earnings per share for the last quarter, exceeding analysts' expectations by $4.46 and showing a revenue increase of 3.6% year-over-year.

Sovran Advisors LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,020 shares of the biopharmaceutical company's stock, valued at approximately $2,750,000.

Several other large investors have also recently modified their holdings of REGN. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after purchasing an additional 686 shares in the last quarter. American Assets Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $427,000. Tidal Investments LLC grew its stake in shares of Regeneron Pharmaceuticals by 21.5% during the fourth quarter. Tidal Investments LLC now owns 7,715 shares of the biopharmaceutical company's stock worth $5,496,000 after acquiring an additional 1,365 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Regeneron Pharmaceuticals by 54.3% during the fourth quarter. Two Sigma Investments LP now owns 34,543 shares of the biopharmaceutical company's stock worth $24,606,000 after acquiring an additional 12,154 shares during the last quarter. Finally, Vident Advisory LLC grew its stake in shares of Regeneron Pharmaceuticals by 228.7% during the fourth quarter. Vident Advisory LLC now owns 4,677 shares of the biopharmaceutical company's stock worth $3,332,000 after acquiring an additional 3,254 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $6.72 during trading hours on Friday, hitting $591.99. 2,177,965 shares of the company's stock were exchanged, compared to its average volume of 914,839. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a market cap of $62.75 billion, a P/E ratio of 14.92, a P/E/G ratio of 2.00 and a beta of 0.35. The firm has a 50 day moving average of $567.77 and a two-hundred day moving average of $575.90. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company posted $11.56 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein boosted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 27th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.